Mobile

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2010-020150-34

A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Main objective: To assess the safety and tolerability of inactivated VZV vaccine in recipients of autologous HCT and to assess the impact of inactivated VZV vaccine on the development of HZ following autologous HCT

Critère d'inclusion

  • Incidence of Herpes Zoster in recipients of Autologous HCTs

Liens